TABLE 3.
Clinical studies using somatostatin analogs for meningioma treatment.
| Subjects | No. of pts | Somatostatin analog | Dose | mTCs | Tumor response |
Survival |
TT due to AEs | References | ||||
| PR | SD | PD | PFS6 | mPFS/TTP (months) | mOS (months) | |||||||
| Recurrent M | 16 | Sandostatin LAR | 30 mg/4 weeks | 4.5 | 5 | 5 | 6 | 44% | 5 | 7.5 | 0 | (74) |
| Recurrent high-grade M | 9 | Sandostatin LAR | 30–40 mg/4 weeks | 3 | 0 | 3 | 6 | 44% | 4.2 | 18.7 | 0 | (82) |
| Recurrent or progressive M | 11 | Sandostatin LAR | 500 μg 3 times/day | NA | 0 | 8 | 3 | 30% | 3.9 | NA | 0 | (93) |
| Progressive residual M after surgery | 8 | Sandostatin LAR | 30 mg/4 weeks | NA | 0 | 8 | 0 | 100% | NA | NA | 1 | (94) |
| Recurrent or progressive M | 34 | Pasireotide LAR | 60 mg/4 weeks | NA | 0 | 24 | 8 | 32% | 4.2 | NA | 0 | (95) |
AEs, adverse events; M, meningioma; mOS, median overall survival; mPFS, median progression survival; mTCs, median treatment cycles; NA, not-available; PFS6, 6 months progression survival; PR, partial response; Pts, patients; PD, progressive disease; SD, stable disease; TT, treatment interruption; and TTP, time to progression.